In The Lancet, Séverine Vermeire and colleagues 1 report the results of a double-blind, randomised, placebocontrolled phase 2 trial that studied the eff ects of etrolizumab-a humanised monoclonal antibody that selectively binds the β7 subunit of both the α4β7 and αEβ7 integrins-on the induction of remission in patients with moderate-to-severe ulcerative colitis. 124 patients were randomised, and clinical remission at week 10 (the primary endpoint) was achieved in a signifi cantly higher proportion of patients in the etrolizumab groups than in the placebo group (eight patients of 39 analysed in the etrolizumab 100 mg group [21%, 95% CI 7-36], four of 39 in the etrolizumab 300 mg plus loading dose group [10%, 0·2-24], and none of 41 patients in the placebo group). As in the phase 1 study, 2 the treatment was well tolerated. Considering these results, and the fact that the population of patients included in the trial was particularly refractory to other powerful treatments, such as anti-TNFα and immunosuppressants, etrolizumab has great potential to become a new therapeutic option for patients with ulcerative colitis.
Several other fi ndings and features of this study contribute to make it a milestone in trials of ulcerative colitis treatment. First, the proportion of patients with clinical remission at week 10 in the placebo group was nil. In other trials focused on moderate-to-severe ulcerative colitis therapies, [3] [4] [5] [6] similar results have never been reported, and remission in the placebo group has always ranged between 5·4% and 14·9%. One of the main possible explanations of Vermeire and colleagues' observation is the use of central reading for endoscopic scores. This rigorous approach had never been implemented in studies of biological therapies in ulcerative colitis before, but has been shown to be fundamental for both the correct enrolment of patients and the results of multicentre clinical trials in this disease. 7 The level of concordance between local and central endoscopic scoring used by Vermeire and colleagues 1 might confi rm this hypothesis. Furthermore, since the rate of remission was 5% in the placebo group at week 6, the choice of an appropriate timepoint for the assessment of the primary outcome (10 weeks) might have also contributed to the results.
Another key feature of Vermeire and colleagues' study 1 concerns the pharmacodynamics of etrolizumab, including the analysis of β7 occupancy and expression on T-lymphocyte and B-lymphocyte subsets in peripheral blood and colonic tissue, quantifi cation of αE+ cells, and gene expression of cytokines and adhesion molecules. The advantage that etrolizumab has over other anti-adhesion therapies is its potential to interfere with the αEβ7/Ecadherin pathway and thereby reduce intraepithelial leucocytes in the gut. 8 The immunohistochemistry analysis of colonic biopsies in Vermeire and colleagues' study showed an apparent decrease in the proportion of αE+ cells in the intestinal crypt epithelium of patients in the etrolizumab groups, especially in those who achieved clinical remission. The absence of statistical signifi cance for this endpoint might have been because the timepoint for histological examination was too short, assuming that changes in tissue take longer to appear than do other outcomes. A higher number of αE+ cells at baseline seems to be related to clinical remission, representing a possible predictive factor of response to etrolizumab.
Patients assigned to higher doses of the active drug (etrolizumab 300 mg plus loading dose) paradoxically had less clinical benefi t than did those assigned to 100 mg etrolizumab.
1 The investigators discuss their fi ndings in detail, postulating that etrolizumab might also interfere with the migration of other cell types, such as regulatory T cells. Although the possible link between regulatory T cells and α4β7 integrins has already been shown in mice, 9 the mechanisms underlying these results should be further investigated in human beings. The investigators indirectly compare effi cacy outcomes between etrolizumab and
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New era for treatment in diff erentiated thyroid cancer
Multikinase inhibitors were introduced into clinical trials for radioactive iodine-refractory diff erentiated thyroid cancer a decade ago. In The Lancet, Marcia Brose and colleagues 1 report the results of DECISION, the fi rst phase 3 randomised, double-blind, placebo-controlled clinical trial with the multikinase inhibitor sorafenib in diff erentiated thyroid cancer. On the basis of this landmark trial, sorafenib received an orphan designation by the European Medicine Agency in diff erentiated thyroid cancer, 2 and was approved by the US Food and Drug Administration (FDA) for treatment of radioactive iodinerefractory diff erentiated thyroid cancer in November, 2013.
3 Sorafenib is only the fourth drug to be approved by the FDA for treatment of thyroid cancer. Several decades after doxorubicin was introduced for this indication in 1974, 4 vandetanib (2011) and cabozantinib (2012) were approved for medullary thyroid cancer. It is now an exciting time for the specialty as strong collaborative research initiated by academia, industry, and governmental agencies has revolutionised treatment for thyroid cancer.
Thyroid cancer has one of the fastest growing incidences of any cancer in high-income countries. 5 Diff erentiated thyroid cancer accounts for about 90% of all thyroid cancers and includes papillary, follicular, poorly diff erentiated, and Hürthle cell histologies. Although the disease generally has a good prognosis, patients who develop metastatic radioactive iodine-refractory diff erentiated thyroid cancer have an overall survival of only 10-20% at 10 years. 6 Cytotoxic chemotherapy including doxorubicin has yielded disappointing results. 4 In 2003, discovery of oncogenic BRAF mutations in papillary thyroid cancer, 7 with a frequency of approximately 45%, opened a new pathway for drug development. Sorafenib, a serine-threonine kinase inhibitor, designed to target BRAF and subsequently found to have several targets including RET and vascular endothelial growth factor receptor, was being tested at the time in early-phase clinical trials for various cancers.
For our phase 2 clinical trial, 8 the preliminary results showing anticancer activity of sorafenib in diff erentiated thyroid cancer were presented in August, 2005 and were received enthusiastically. Three additional prospective phase 2 trials of sorafenib showed encouraging effi cacy in diff erentiated thyroid cancer (table) . [8] [9] [10] [11] [12] Furthermore, several other multikinase inhibitors that target angiogenesis-eg, sunitinib, pazopanib, and lenvatinib- included diff erent populations of patients with ulcerative colitis, and had diff erent defi nitions of endpoints and timepoint assessments, so any comparison between these trials is premature and potentially unreliable.
In conclusion, the results of the present study confi rm that anti-integrin therapies might be a valid option for the medical management of patients with moderate-tosevere ulcerative colitis, and support further studies (eg, NCT01461317 and NCT02100696) to validate clinical effi cacy and long-term safety of etrolizumab in this group of patients with diffi cult-to-treat ulcerative colitis.
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